Momentum appears strong and positively oriented, with recent trends confirming an improvement in market perception. The stock is benefiting from a dynamic that goes beyond a simple technical rebound, suggesting that the market is anticipating more credible clinical execution or better strategic visibility. For retail investors, however, the stock should still be viewed as a speculative growth name, where market momentum must be monitored alongside scientific risk.